The Excellence of EGF Reported In an International SCI Journal

Professor Hong Jun Pyo of Asan Medical Center announced his clinical study results in the journal ‘Annals of Plastic Surgery’. He stated that incurable diabetes-induced leg ulcers, were completely treated and healed  with EGF and joint medication.

The excellent efficacy of a novel bioengineered drug Easyef, which was developed by Daewoong Pharmaceutical for the first time in Korea, was reported in the April 2006 international SCI journal ‘Annals of Plastic Surgery’. The journal announced and reported the results of a clinical study on the ‘Efficacy of Easyef on chronic diabetic foot ulcers’ conducted by Hong Jun Pyo, a Professor of Plastic Surgery at Asan Medical Center. In this study, Professor Hong reported that among eighty-nine patients with chronic diabetic foot ulcers, sixty-eight patients whose conditions had not improved with advanced dressings alone were medicated with Easyef dermal solution along with advanced dressings twice a day. Fifty-two patients (72%) were completely cured.

This result is significantly different and superior from that of PDGF, another wound healing solution, whose healing rate was only 48%~57.5%. In a specific case when Easyef was administered to a woman who had not recovered from foot ulcers with advanced dressings alone, the woman started to heal in the 4th week and was completely healed by the 8th week.

Professor Hong also reported on a case of a 46-year-old man whose diabetic foot ulcers caused him to have his toes amputated. When the patient received treatment combined with Easyef, his amputated parts were completely concealed by skin and healed perfectly in six months. Based on study results, Professor Hong anticipated that we would be able to expect a positive effect of promoting healing of incurable chronic diabetic foot ulcers if patients were medicated with advanced dressings combined with Easyef.

Easyef, which is a novel bioengineering drug developed by Daewoong Pharmaceutical for the first time in Korea, entered the market in 2001 and its finished products are being exported to Jordan since last year.

Daewoong is now actively promoting and preparing its advance into the US and European markets. It plans a full-scale advance into Asia based on exports to the Middle East, China, and Southeast Asia. Daewoong Pharmaceutical plans to make Easyef the best wound healing drug in the world by extending the number of wounds to which it can be applied and its drug formation.